DR. WAYNE HARRY KAESEMEYER, MD
Osteopathic Medicine in Augusta, GA
License number
Georgia 22800
Category
Osteopathic Medicine
Type
Cardiovascular Disease
Address
Address
1021 Biotech Park SUITE 2, Augusta, GA 30901
Phone
(706) 722-4688
(706) 722-8194 (Fax)
(706) 722-8194 (Fax)
Personal information
See more information about WAYNE HARRY KAESEMEYER at radaris.comName
Address
Phone
1021 15Th St, Augusta, GA 30901
1021 15Th St, Augusta, GA 30901
2433 Mcdowell St, Augusta, GA 30904
Professional information
Wayne Harry Kaesemeyer, Augusta GA
Specialties:
Internist
Address:
1021 15Th St, Augusta, GA 30901
Education:
Wake Forest University, School of Medicine - Doctor of Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine
Therapeutic Mixture Useful In Inhibiting Lesion Formation After Vascular Injury
US Patent:
6425881, Jul 30, 2002
Filed:
Apr 16, 1999
Appl. No.:
09/293392
Inventors:
Wayne H. Kaesemeyer - Augusta GA
Assignee:
Nitrosystems, Inc. - Augusta GA
International Classification:
A61M 1100
US Classification:
604 93, 514 53, 514 94, 514269
Abstract:
Vessels are treated with a mixture of L-arginine and an agent which enhances the biotransformation of L-arginine into NO. The incidents associated with restenosis are expected to be substantially reduced and prevented providing for a reduced incidence of restenosis as a result of the injury.
Method Of Stimulating Nitric Oxide Synthase
US Patent:
6465516, Oct 15, 2002
Filed:
Oct 18, 1999
Appl. No.:
09/420328
Inventors:
Wayne H. Kaesemeyer - Augusta GA
Assignee:
Nitrosystems, Inc. - Augusta GA
International Classification:
A61K 3122
US Classification:
514548, 514419, 514460
Abstract:
A method for treating a subject who would benefit from increased nitric oxide production comprising administering inhibitors of Hmg-CoA-Reductase is disclosed for the treatment of diseases related to endothelial dysfunction.
Combination Therapy For Endothelial Dysfunction, Angina And Diabetes
US Patent:
2006020, Sep 14, 2006
Filed:
Mar 10, 2006
Appl. No.:
11/373658
Inventors:
Wayne Kaesemeyer - Augusta GA, US
International Classification:
A61K 31/537, A61K 31/401, A61K 31/366, A61K 31/22
US Classification:
514237500, 514423000, 514460000, 514548000
Abstract:
The combination of a HMG CoA reductase inhibitor like a statin, such as simvastatin, with a pFox inhibitor such as trimetazidine (“Simetazidine”) is particularly advantageous for treatment of end-stage complications, such as acute coronary syndrome (ACS) and chronic angina, especially in type II diabetics. The combination therapy is also useful in the treatment and/or prevention of chronic heart failure (CHF) and peripheral arterial disease (PAD). The combination of a nitric oxide (NO) mechanism with increased NO production with pFox inhibition simultaneously treats both the effect and the cause of angina. One or more oral hypoglycemic compounds (biguanides, insulin sensitizers, such as thiazolidinediones, α-glucosidase inhibitors, insulin secretagogues, and dipeptidyl peptidase IV inhibitors), protein kinase C (PKC) inhibitors, and acetyl-CoA carboxylase inhibitors can also be used in combination with the HMG CoA reductase inhibitors and/or pFox inhibitors, especially in type II diabetics, to control glucose levels and treat endothelial dysfunction. The drugs can be given in combination (e.g. a single tablet) or in separate dosage forms, administered simultaneously or sequentially. In the preferred form the statin is given in a dose of between 5 and 80 mg/day in two separate doses, and the pFox inhibitor is administered in a sustained or extended dosage formulation at a dose of 20 mg three times a day or 35 mg two times a day. The dose of the oral hypoglycemic, PKC inhibitor, or acetyl-CoA carboxylase inhibitor varies with the type of drug used.
Method And Formulation For Treating Vascular Disease
US Patent:
2005008, Apr 21, 2005
Filed:
Aug 5, 2004
Appl. No.:
10/912717
Inventors:
Wayne Kaesemeyer - Augusta GA, US
International Classification:
A61K031/198
US Classification:
514565000
Abstract:
A therapeutic mixture comprised of L-arginine and inhibitors of Hmg-CoA-Reductase is disclosed for the treatment of diseases related to endothelial dysfunction, wherein the endothelial dysfunction is relieved by stimulating the constitutive form of nitric oxide synthase (cNOS) to produce native nitric oxide (NO).
Pharmaceutical Composition Comprising Citrulline
US Patent:
7381731, Jun 3, 2008
Filed:
Jan 23, 2004
Appl. No.:
10/763309
Inventors:
Wayne H. Kaesemeyer - Augusta GA, US
Assignee:
Angiogenix, Inc. - Burlington CA
International Classification:
A61K 31/435, A61K 31/40, A61K 31/405, A61K 31/35, A61K 31/22, A61K 31/20, A61K 31/195
US Classification:
514277, 514408, 514415, 514451, 514546, 514559, 514563
Abstract:
Embodiments of the present invention include compositions and pharmaceutical compositions comprising citrulline and Hmg-CoA reductase inhibitors. Further embodiments relate to the use of such composition treat subjects and stimulating nitric oxide synthase.
Method And Formulation For Treating Vascular Disease
US Patent:
5968983, Oct 19, 1999
Filed:
Apr 10, 1997
Appl. No.:
8/833842
Inventors:
Wayne H. Kaesemeyer - Augusta GA
Assignee:
Nitrosystems, Inc - Augusta GA
International Classification:
A01N 3712
US Classification:
514564
Abstract:
A therapeutic mixture comprised of L-arginine and inhibitors of Hmg--CoA-Reductase is disclosed for the treatment of diseases related to endothelial dysfunction, wherein the endothelial dysfunction is relieved by stimulating the constitutive form of nitric oxide synthase (cNOS) to produce native nitric oxide (NO).
Controlled Release Arginine Formulations
US Patent:
2011021, Sep 1, 2011
Filed:
Mar 15, 2011
Appl. No.:
13/048736
Inventors:
Wayne H. KAESEMEYER - Augusta GA, US
International Classification:
A61K 9/22, A61K 31/198, A61P 25/00
US Classification:
424468, 514561
Abstract:
A sustained release formulation of L-arginine alone or in combination with an agent which enhances the biotransformation of L-arginine into NO is described herein. FIG. A shows a schematic representation of proposed L-arginine dependent and independent pathways.
Therapeutic Mixture Of Hmg-Coa Reductase Inhibitors
US Patent:
2003011, Jun 19, 2003
Filed:
Oct 11, 2002
Appl. No.:
10/269847
Inventors:
Wayne Kaesemeyer - Augusta GA, US
International Classification:
A61K031/401, A61K031/366, A61K031/198, A61K031/225
US Classification:
514/423000, 514/460000, 514/548000, 514/565000
Abstract:
Therapeutic mixtures of statins alone or in combination with L-arginine are described herein.
Formulations For Treating Disease And Methods Of Using Same
US Patent:
6239172, May 29, 2001
Filed:
Jan 7, 1999
Appl. No.:
9/226580
Inventors:
Wayne H. Kaesemeyer - Augusta GA
Assignee:
NitroSystems, Inc. - Augusta GA
International Classification:
A01N 4316, A61K 3135
US Classification:
514460
Abstract:
A therapeutic mixture comprised of L-arginine and angiogenic growth factors is disclosed for the treatment of diseases related to endothelial dysfunction.